Michael Gray compensation by year
Enliven Therapeutics Summary Compensation Table · all 3 fiscal years held| Component | FY2019 | FY2020 | FY2021 |
|---|---|---|---|
| Salary | $281,458 | $392,740 | $454,454 |
| Bonus | $88,659 | $134,263 | $172,692 |
| Stock awards | $0 | $0 | $0 |
| Option awards | $897,219 | $0 | $575,168 |
| Non-equity incentive | $0 | $0 | $0 |
| Pension and deferred compensation | $0 | $0 | $0 |
| All other | $4,403 | $14,423 | $14,090 |
| Total | $1,271,739 | $541,426 | $1,216,404 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Enliven Therapeutics, Inc. DEF 14A filed April 22, 2022, accession 0001193125-22-114052, and prior-year filings.
How this page was built: the Enliven Therapeutics, Inc. filed document, accession 0001193125-22-114052. Every figure is read from that document and cited to the page and table it appears in. Filed April 22, 2022.
Equity holdings
unvested awards at FY2021 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| Option | 21,407 | — | $4.92 |
| Option | 60,800 | — | $13.83 |
| Option | 84,116 | — | $4.92 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Enliven Therapeutics, Inc.'s FY2021 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
2 Form 4 lines since the FY2021 proxy (filed April 22, 2022)current to 2026-11-21 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2023-02-22 | Sale | — | 9,856 | $4.67 | 27,610 |
| 2023-01-30 | Sale | — | 3,596 | $3.92 | 37,466 |
The 2 most recent of 2 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
Enliven Therapeutics’s named executive officers, FY2021
as the company reported each| Named executive officer | Role | FY2021 total |
|---|---|---|
| Rahul Ballal | President and Chief Executive Officer | $1,951,029 |
| Kenneth Attie | Chief Medical Officer | $1,621,940 |
| Michael Gray · this page | Chief Financial Officer and Chief Operating Officer | $1,216,404 |
The full Enliven Therapeutics compensation record
free company briefThis page is one person within Enliven Therapeutics's record. The company brief lists every named executive, each linking to their own page.
Compensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Enliven Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.